Rapid Dose Therapeutics Corp.
RDTCF
$0.08
-$0.01-15.56%
OTC PK
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.06% | 30.24% | 90.13% | 225.80% | 112.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.06% | 30.24% | 90.13% | 225.80% | 112.90% |
| Cost of Revenue | 47.92% | 57.51% | 166.38% | 267.13% | 119.87% |
| Gross Profit | 12.93% | 14.57% | 47.88% | 191.15% | 107.28% |
| SG&A Expenses | -29.37% | -31.19% | -31.41% | 94.68% | 76.67% |
| Depreciation & Amortization | 159.14% | 168.66% | 56.84% | -72.97% | -68.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.68% | -11.63% | -7.74% | 39.82% | 46.47% |
| Operating Income | 33.28% | 36.81% | 48.73% | -8.89% | -26.93% |
| Income Before Tax | 17.64% | 25.06% | 44.19% | 23.13% | -38.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.64% | 25.06% | 44.19% | 23.13% | -38.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.64% | 25.06% | 44.19% | 23.13% | -38.03% |
| EBIT | 33.28% | 36.81% | 48.73% | -8.89% | -26.93% |
| EBITDA | 33.25% | 37.93% | 49.99% | -16.95% | -49.68% |
| EPS Basic | 22.50% | -12.31% | 48.68% | 33.09% | -14.29% |
| Normalized Basic EPS | 22.00% | -12.20% | 48.94% | 7.94% | -16.28% |
| EPS Diluted | 22.50% | -12.31% | 48.68% | 33.09% | -14.29% |
| Normalized Diluted EPS | 22.00% | -12.20% | 48.94% | 7.94% | -16.28% |
| Average Basic Shares Outstanding | 6.04% | -32.95% | 7.90% | 14.55% | 20.14% |
| Average Diluted Shares Outstanding | 6.04% | -32.95% | 7.90% | 14.55% | 20.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |